Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 10:12 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 2,647 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Topical Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A 21 Day Pharmacokinetics Study in Papulopustular Rosacea

NCT02028286
View directory record Official record
Conditions
Papulopustular Rosacea
Interventions
CLS001
Drug
Lead sponsor
Maruho Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2014
U.S. locations
2
States / cities
Hackensack, New Jersey • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Apr 14, 2014 · Synced Oct 21, 2026, 10:12 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Evaluation of a Low-fluoride Anticaries Toothpaste

NCT01094210
View directory record Official record
Conditions
Tooth Abnormality
Interventions
Fluorides, Topical
Drug
Lead sponsor
Indiana Nanotech, LLC
Other
Eligibility
18 Years to 50 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Mar 25, 2015 · Synced Oct 21, 2026, 10:12 AM EDT
Completed Phase 4 Interventional Results available

A Study to Evaluate the Efficacy and Safety of a Leave-in Spray in Subjects With Head Lice Infestation

NCT05565820
View directory record Official record
Conditions
Pediculosis Capitis, Lice Infestations, Head Lice
Interventions
Vamousse Spray 'n' Go, Nix Creme Rinse Lice Treatment
Other · Drug
Lead sponsor
Alliance Pharmaceuticals
Industry
Eligibility
2 Years to 75 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Feb 24, 2025 · Synced Oct 21, 2026, 10:12 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Anti-pruritic Effectiveness of ASN008 in Adults With Mild to Moderate Atopic Dermatitis

NCT05870865
View directory record Official record
Conditions
Dermatitis, Atopic, Pruritus
Interventions
ASN008, ASN008 Matching Vehicle
Drug · Other
Lead sponsor
Formation Bio, Inc.
Industry
Eligibility
18 Years and older
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
27
States / cities
Scottsdale, Arizona • Hot Springs, Arkansas • Beverly Hills, California + 23 more
Source: ClinicalTrials.gov public record
Updated May 16, 2025 · Synced Oct 21, 2026, 10:12 AM EDT
Completed Phase 2Phase 3 Interventional

Safety and Efficacy of Luliconazole Solution, 10% in Subjects With Mild to Moderate Onychomycosis

NCT01431820
View directory record Official record
Conditions
Distal and Lateral Subungual Onychomycosis
Interventions
Luliconazole Solution, 10%, Vehicle Solution
Drug
Lead sponsor
Topica Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
334 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
28
States / cities
Phoenix, Arizona • Los Angeles, California • San Diego, California + 23 more
Source: ClinicalTrials.gov public record
Updated Nov 30, 2015 · Synced Oct 21, 2026, 10:12 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Evaluation of Pharmacodynamic Effects on Ovulation and Cycle Control

NCT01250210
View directory record Official record
Conditions
Ovulation Suppression
Interventions
levonorgestrel and ethinyl estradiol
Drug
Lead sponsor
Agile Therapeutics
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
123 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
11
States / cities
Tucson, Arizona • San Diego, California • Denver, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2018 · Synced Oct 21, 2026, 10:12 AM EDT
Enrolling by invitation Not applicable Interventional

Little NIRVANA for Pediatric Pain and Anxiety

NCT06795126
View directory record Official record
Conditions
Acute Pain, Procedural Anxiety, Pediatric ALL, Emergency Medicine, IV Access
Interventions
Little NIRVANA
Other
Lead sponsor
Nationwide Children's Hospital
Other
Eligibility
2 Years to 8 Years
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 21, 2026, 10:12 AM EDT
Completed Phase 1 Interventional

Topical Agent for Treatment of Red Skin

NCT00279890
View directory record Official record
Conditions
Rosacea, Bilaterally Symmetric Red Skin on Cheeks
Interventions
Topical SR-01
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 60 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated May 23, 2011 · Synced Oct 21, 2026, 10:12 AM EDT
Enrolling by invitation Not applicable Interventional Accepts healthy volunteers

Observing Performance of Haptic Vibrotactile Trigger Technology by Measuring Changes in Resting Metabolic Rate: Assessment and Analysis

NCT07781384
View directory record Official record
Conditions
Resting Metabolic Rate, Energy Metabolism, Haptic Technology, Vibrotactile Stimulation
Interventions
IGNITE Patch (Active), Inactive patch
Device
Lead sponsor
SuperPatch Limited LLC
Industry
Eligibility
18 Years to 85 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Tyrone, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Oct 21, 2026, 10:12 AM EDT
Terminated Phase 2 Interventional

ALA-PDT Versus Vehicle PDT for Treatment of AK and Reduction of New NMSC in Solid Organ Transplant Recipients

NCT00865878
View directory record Official record
Conditions
Actinic Keratoses, Skin Neoplasms
Interventions
Aminolevulinic Acid, Vehicle
Drug · Other
Lead sponsor
DUSA Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
7
States / cities
Irvine, California • San Francisco, California • Miami, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2011 · Synced Oct 21, 2026, 10:12 AM EDT
Terminated Phase 3 Interventional Results available

Besifloxacin Ophthalmic Suspension Verses Gatifloxacin Ophthalmic Solution in Neonates With Bacterial Conjunctivitis

NCT01330355
View directory record Official record
Conditions
Bacterial Conjunctivitis
Interventions
Besivance, Gatifloxacin
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
1 Day to 31 Days
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 3, 2014 · Synced Oct 21, 2026, 10:12 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Pilot Study of the Safety of MC-1101 in Both Normal Volunteers and Patients With Early Dry AMD

NCT01013376
View directory record Official record
Conditions
Age-Related Macular Degeneration
Interventions
MC-1101, Vehicle
Drug
Lead sponsor
MacuCLEAR, Inc.
Industry
Eligibility
50 Years and older
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 13, 2009 · Synced Oct 21, 2026, 10:12 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study Investigating the Safety, Tolerability, and Efficacy of Elamipretide Topical Ophthalmic Solution for the Treatment of Fuchs' Corneal Endothelial Dystrophy (FCED)

NCT02653391
View directory record Official record
Conditions
Fuchs' Corneal Endothelial Dystrophy (FCED)
Interventions
Part A Elamipretide 1.0% Ophthalmic Solution, Part B Elamipretide 3.0% Ophthalmic Solution, Part A Placebo, Part B Placebo
Drug
Lead sponsor
Stealth BioTherapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
2
States / cities
Edgewood, Kentucky • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 17, 2021 · Synced Oct 21, 2026, 10:12 AM EDT
Completed Not applicable Interventional Results available

Evaluation of the Effects of HP828-101 Versus Standard of Care in the Management of Partial or Full Thickness Wounds

NCT00971048
View directory record Official record
Conditions
Diabetic Foot Ulcers, Pressure Ulcers
Interventions
HP828-101, Hydrogel/Hydrocolloid
Device
Lead sponsor
Healthpoint
Industry
Eligibility
18 Years and older
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
11
States / cities
Bakersfield, California • Chula Vista, California • Fresno, California + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2014 · Synced Oct 21, 2026, 10:12 AM EDT
Completed Phase 3 Interventional Results available

Comparison of Efficacy and Safety of TachoSil® Versus Surgicel® Original for the Secondary Hemostatic Treatment of Needle Hole Bleeding in Vascular Surgery

NCT01500135
View directory record Official record
Conditions
Bleeding
Interventions
TachoSil®, Surgicel® Original
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
37
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Long Beach, California + 25 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2017 · Synced Oct 21, 2026, 10:12 AM EDT
Completed Early Phase 1 Interventional

SDF Application in Oral Cancer Patients to Prevent Dental Caries

NCT05403125
View directory record Official record
Conditions
Dental Caries
Interventions
silver diamine fluoride, 38%, Sodium fluoride gel, 5000 PPM
Device
Lead sponsor
Texas A & M University Baylor College Of Dentistry
Other
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 17, 2025 · Synced Oct 21, 2026, 10:12 AM EDT
Recruiting Not applicable Interventional

Topical Intranasal Anesthetic Block for Reducing the Pain of Botulinum Toxin Injections for Chronic Migraine

NCT07571889
View directory record Official record
Conditions
Pain From onabotulinumtoxinA Injections
Interventions
onabotulinumtoxinA prophylaxis with Lidocaine, OnabotulinumtoxinA prophylaxis with Saline
Procedure
Lead sponsor
Association of Migraine Disorders
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
East Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 21, 2026, 10:12 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of NAFT-600 in Subjects With Tinea Pedis

NCT01289015
View directory record Official record
Conditions
Tinea Pedis
Interventions
NAFT-600 ( naftin 2 % gel ), Placebo
Drug
Lead sponsor
Merz North America, Inc.
Industry
Eligibility
12 Years and older
Enrollment
855 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
22
States / cities
Phoenix, Arizona • San Diego, California • San Francisco, California + 19 more
Source: ClinicalTrials.gov public record
Updated Sep 26, 2013 · Synced Oct 21, 2026, 10:12 AM EDT
Terminated Not applicable Interventional Results available

Acitretin or Tazarotene Gel and Excimer Laser for Treatment of Psoriasis

NCT01094717
View directory record Official record
Conditions
Psoriasis
Interventions
Acitretin 25Mg Oral Capsule, Excimer laser, Tazarotene 0.1% Gel,Top, Sham excimer laser
Drug · Device
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 26, 2019 · Synced Oct 21, 2026, 10:12 AM EDT
Completed Phase 3 Interventional

A Multi-Center Environmental Study for the Treatment of Moderate to Severe Ocular Allergic Conjunctivitis

NCT02492321
View directory record Official record
Conditions
Allergic Conjunctivitis (AC)
Interventions
EBI-005, Placebo Comparator
Drug
Lead sponsor
Eleven Biotherapeutics
Industry
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
11
States / cities
Morrow, Georgia • Louisville, Kentucky • Andover, Massachusetts + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2016 · Synced Oct 21, 2026, 10:12 AM EDT
Completed Phase 3 Interventional Results available

Open-Label Extension Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque Psoriasis

NCT04286607
View directory record Official record
Conditions
Chronic Plaque Psoriasis
Interventions
Topical roflumilast
Drug
Lead sponsor
Arcutis Biotherapeutics, Inc.
Industry
Eligibility
2 Years to 11 Years
Enrollment
337 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
68
States / cities
Scottsdale, Arizona • Beverly Hills, California • Encinitas, California + 58 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 21, 2026, 10:12 AM EDT
Completed Not applicable Interventional Results available

Vapocoolant (Pain Ease Medium Stream) for Intravenous Lines in Emergency Department Patients

NCT01670487
View directory record Official record
Conditions
Pain
Interventions
Vapocoolant, Sterile water
Device
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 80 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 27, 2025 · Synced Oct 21, 2026, 10:12 AM EDT
Completed Phase 2 Interventional

A Safety Study of 188-0551 Spray Versus Reference Listed Drug (RLD) in Adult Subjects With Plaque Psoriasis

NCT04080206
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
188-0551 Spray, RLD
Drug
Lead sponsor
Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
3
States / cities
Scottsdale, Arizona • Thousand Oaks, California • Miami, Florida
Source: ClinicalTrials.gov public record
Updated May 10, 2021 · Synced Oct 21, 2026, 10:12 AM EDT
Completed Phase 2 Interventional

Fibroblast Growth Factor Regeneration of Tympanic Membrane Perforations

NCT04960384
View directory record Official record
Conditions
Tympanic Membrane Perforation
Interventions
FGF-2, Placebo
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 21, 2026, 10:12 AM EDT